Zacks Research Issues Positive Outlook for WST Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Zacks Research increased their Q3 2026 EPS estimates for shares of West Pharmaceutical Services in a report released on Thursday, August 13th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $2.14 for the quarter, up from their previous forecast of $2.10. Zacks Research has a “Hold” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $8.94 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2026 earnings at $2.24 EPS, FY2026 earnings at $8.88 EPS, Q1 2027 earnings at $2.15 EPS, Q2 2027 earnings at $2.47 EPS, Q3 2027 earnings at $2.36 EPS, Q4 2027 earnings at $2.40 EPS, FY2027 earnings at $9.38 EPS, Q1 2028 earnings at $2.33 EPS, Q2 2028 earnings at $2.83 EPS and FY2028 earnings at $10.74 EPS.

Other research analysts have also recently issued research reports about the stock. KeyCorp boosted their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Stephens reaffirmed an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Evercore reiterated an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, Wolfe Research assumed coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $346.78 on Friday. The business has a 50-day simple moving average of $345.78 and a 200-day simple moving average of $295.38. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services has a one year low of $223.83 and a one year high of $386.00. The company has a market cap of $24.41 billion, a PE ratio of 44.40, a P/E/G ratio of 2.46 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS.

Institutional Trading of West Pharmaceutical Services

Several hedge funds have recently made changes to their positions in WST. Addison Advisors LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $28,000. Avalon Trust Co acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the 4th quarter worth approximately $25,000. Bayban purchased a new stake in shares of West Pharmaceutical Services during the 4th quarter worth approximately $27,000. Finally, Private Trust Co. NA grew its holdings in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks raised several earnings forecasts. Estimates increased for Q3 2026 to $2.14 from $2.10, Q4 2026 to $2.24 from $2.20, FY2026 to $8.88 from $8.50, Q1 2027 to $2.15 from $2.09, Q3 2027 to $2.36 from $2.21, FY2027 to $9.38 from $9.24, and FY2028 to $10.74 from $10.48. These revisions suggest improving expectations for West’s longer-term growth and support the positive earnings case. West Pharmaceutical Services stock information
• Positive Sentiment: The upgrades follow West Pharmaceutical’s recent quarterly performance, when the company exceeded earnings and revenue expectations and raised its 2026 outlook. Faster growth in high-value products, wider margins, and stronger projected earnings have helped reinforce the company’s investment story. WST Q2 beat and raised 2026 outlook
• Neutral Sentiment: Not all revisions were positive: Zacks trimmed Q2 2027 EPS to $2.47 from $2.48, Q4 2027 EPS to $2.40 from $2.47, and Q2 2028 EPS to $2.83 from $2.94. The changes are relatively modest, and Zacks maintained its Hold rating.
• Negative Sentiment: Zacks downgraded WST from “Strong Buy” to “Hold.” The change may weigh on sentiment because it signals that the stock’s expected return has become less compelling after its rally. At approximately $346.78, West trades at about 44 times earnings, leaving limited room for execution or forecast disappointments. Zacks.com
• Negative Sentiment: Although West’s growth, margins, and earnings outlook remain attractive, analysts note that its premium valuation raises the bar for additional gains and increases downside risk if growth slows. Should investors buy WST as HVP growth meets a premium valuation?

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.